Nov 1, 2008
By:
Brittany Agro, Assistant Editor
|
Top Rx Club Award winners exhibit qualities that ironically juxtapose industry's paradigm (pdf)
In pursuit of innovation, Pharma is increasingly practicing—and attempting to perfect—the science of doing deals. Pharm Exec asked a blue-chip panel of insiders to evaluate how well the experiment is working.
Dec 1, 2007
By:
Joanna Breitstein
|
Science is the lifeblood of pharma, of course. But these days, science isn't just what you produce in your own labs. It's what you can license, buy, partner on, or gain through acquisition. Which means that, increasingly, deals are the lifeblood of pharma.
Nov 1, 2007
By:
Joanna Breitstein
|
Photos from the awards ceremony of the first US Prix Galien, September 25, 2007 in New York City.
In their twilight years, old brands are increasingly being snapped up by specialty marketers rather than kicked to the curb
Oct 1, 2007
By:
Albert I. Wertheimer, Ellen F. Loh, Lawrence G. Poli
|
Very few drugs live forever. Barring remarkable scientific advances and radical market dynamics, most drugs hit old age—and sharply declining sales—several years before their patent expires. But some drugs go out with a bang, not a whimper.
Our sixth annual report dives deep into the numbers to discover the industry's true top performers—and how the cookie really crumbles
Sep 1, 2007
By:
Bill Trombetta
|
For the sixth year in a row, Pharm Exec invites Professor Bill Trombetta of St. Joseph’s University to analyze the pharma industry's financial performance with a battery of business metrics, old and new. The highlights: Genentech pulls ahead of its longtime rival, Amgen. Forest delivers another strong performance, despite dropping revenue. Schering-Plough is building enterprise value. Biogen Idec racks up a stellar profit margin. And Merck? Well, Merck is back, baby. And the winner is…
Small profit margins and high litigation risks drove most companies out of the vaccine business decades ago. As a possible pandemic looms, pharma re-enters the fray. Is it too late?
Dec 1, 2005
By:
Anthony Tao
|
Like the course of a pandemic itself, the great avian influenza scare came in waves. In 1997, the first case of the now infamous H5N1 strain of bird flu emerged in Hong Kong, infecting 18 people and killing six. In late 2003 it struck again—more than 120 people fell ill and at least 60 died over the next two years. Then this fall, David Nabarro, MD, the UN coordinator for avian and human influenza, shocked everyone when he said a bird flu pandemic could claim up to 150 million lives—a figure the World Health Organization (WHO) quickly retracted.
A YEAR of THREATS
Dec 1, 2005
By:
Patrick Clinton
|
Medicare Part D launches. $23 billion worth of patents expire. FDA wrestles with safety issues. Pharma prepares for unprecedented cost cutting and restructuring. 2006 promises to be banner year—if you like roller coasters.
Dec 1, 2005
By:
Grant Winter
|
Despite heightened scrutiny from industry advocates and the beginnings of self-imposed regulation, pharma companies' violations of DTC regulations have been getting worse, says Tom Abrams, director of FDA's Division of Drug Marketing, Advertising, and Communications (DDMAC). Abrams has been on all sides of drug marketing, from receiving promotions as a pharmacist to creating promotions as a member of industry to regulating promotions as the head of DDMAC. As such, he's in good position to see the big picture.
Dry? Not quite. Instead of 1990s-style blockbusters, pharma's new molecules are niche drugs, cancer treatments and—at last—innovative mechanisms for troublesome targets.
Dec 1, 2005
By:
Ron Feemster
|
Dry? Not quite. Instead of 1990s-style blockbusters, pharma's new molecules are niche drugs, cancer treatments and—at last—innovative mechanisms for troublesome targets.
